FDA Flavored Vape Guidance Enters White House Review: What It Means for PMTA Applications and the Future of Flavored ENDS

A new federal policy affecting flavored vaping products is quietly moving through the regulatory pipeline in Washington. 

The U.S. Food and Drug Administration has submitted draft guidance related to flavored electronic nicotine delivery systems (ENDS) to the White House for review, marking the next step in the agency’s evolving approach to regulating flavored vaping products in the United States. 

While the document has not yet been released publicly, its arrival at the White House signals that federal regulators are preparing to clarify how flavored vapor products will be evaluated under the FDA’s premarket authorization system. 

For manufacturers, retailers, and consumers alike, the guidance could help shape the future of flavored vaping in the U.S. 

 

A New Step in the Regulatory Process 

 

The draft guidance, titled “Statement of Policy – Considerations for Flavored Electronic Nicotine Delivery Systems (ENDS) Premarket Applications,” was submitted by the U.S. Department of Health and Human Services and the FDA for review under Executive Order 12866. 

That order requires significant regulatory actions to be reviewed by the White House’s Office of Information and Regulatory Affairs (OIRA) before they are formally issued. 

The guidance entered the review process on February 18 and currently appears on the federal regulatory agenda under Regulatory Identification Number 0910-ZC78. A meeting related to the proposal has been scheduled for March 10. 

This step does not mean the policy is finalized, but it indicates the agency is moving closer to releasing updated direction for manufacturers seeking authorization to sell flavored vaping products in the U.S. 

 

What the Guidance Is Expected to Address 

 

Under the Tobacco Control Act, manufacturers must receive FDA authorization before introducing new tobacco products to the market. This includes vapor products, which are regulated through the Premarket Tobacco Product Application (PMTA) process. 

The PMTA system requires companies to demonstrate that marketing their product would be “appropriate for the protection of public health,” often referred to as the APPH standard. 

The upcoming guidance is expected to focus specifically on how manufacturers should approach flavored vaping products when preparing these applications. 

In practice, that likely means outlining the types of scientific evidence, consumer behavior data, and risk assessments the FDA expects companies to provide when submitting PMTAs for flavored products. 

The goal, according to the agency, is to clarify how flavored products should be evaluated within the existing regulatory framework. 

 

Why Flavors Remain a Central Issue 

 

Few topics in nicotine regulation generate as much debate as flavors. 

Public health advocates have long argued that certain flavors may appeal to youth, while harm-reduction advocates and industry groups point out that flavors also play an important role in helping adult smokers switch away from combustible cigarettes. 

The challenge for regulators has been balancing these two realities. 

Research shows that flavored vaping products are commonly used by adults who have transitioned away from smoking, but those same flavor profiles can also attract experimentation among younger populations. 

As a result, regulators have increasingly focused on whether companies can demonstrate that their products provide benefits to adult smokers while minimizing youth uptake. 

The upcoming guidance may provide clearer expectations for how manufacturers can make that case. 

 

A Window for Stakeholder Engagement 

 

Because the guidance is currently under review by OIRA, there is still an opportunity for industry groups, public health organizations, and other stakeholders to engage with regulators before the policy is finalized. 

OIRA’s review process allows outside groups to request meetings with federal officials to discuss potential economic impacts, scientific evidence, and policy considerations related to the proposed action. 

These discussions often play an important role in shaping how regulatory policies are implemented before they are formally released. 

For companies navigating the complex PMTA process, this stage of review may be one of the last chances to raise concerns or suggest improvements to the guidance before it becomes official FDA policy. 

 

A Policy Moment That Could Shape the Market 

 

The FDA has already issued marketing authorization for a limited number of vapor products through the PMTA process, but thousands of applications have been denied or remain under review. 

Many manufacturers argue that the agency’s expectations have evolved over time, making it difficult to predict what types of evidence are required for approval. 

If the new flavored ENDS guidance provides clearer standards, it could help manufacturers better understand how to structure their applications moving forward. 

At the same time, stakeholders will be watching closely to see whether the policy sets a higher evidentiary bar for flavored products or offers a clearer pathway for demonstrating compliance with the public health standard. 

 

What Comes Next 

 

Once OIRA completes its review, the FDA can publish the guidance as a draft document for industry and public comment. 

At that point, stakeholders will have the opportunity to review the full policy and provide feedback before it is finalized. 

For an industry that has spent years navigating regulatory uncertainty, the guidance could represent either a new layer of complexity—or long-awaited clarity. 

Either way, the outcome will likely influence how flavored vaping products are evaluated in the United States for years to come.